Harald Kolmar

Respiratory syncytial virus–approved mAb Palivizumab as ligand for anti-idiotype nanobody-based synthetic cytokine receptors

S. Smits, D. Floss, Jens M. Moll, 2023, The Journal of biological chemistry.

Balancing the Affinity and Tumor Cell Binding of a Two-in-One Antibody Simultaneously Targeting EGFR and PD-L1

Julia Harwardt, K. Schoenfeld, Harald Kolmar, 2024, Antibodies.

Conditional activation of an anti-IgM antibody-drug conjugate for precise B cell lymphoma targeting

Julia Harwardt, Adrian Elter, Jan Habermann, 2023, Frontiers in immunology.

Bispecific killer cell engagers employing species cross-reactive NKG2D binders redirect human and murine lymphocytes to ErbB2/HER2-positive malignancies

Julia Harwardt, P. Oberoi, Jordi Pfeifer Serrahima, 2024, Frontiers in immunology.

Better safe than sorry: dual targeting antibodies for cancer immunotherapy

Julia Harwardt, K. Schoenfeld, Harald Kolmar, 2024, Biological chemistry.